Frequency Therapeutics plans on asking the FDA to fast track FX-322, citing recent studies that link hearing loss to other diseases like depression and dementia

This exciting information was found in a local news story about Frequency Therapeutics and FX-322 posted last night.

Local company working on treatment to reverse hearing loss
https://www.wcvb.com/article/local-company-working-on-treatment-to-reverse-hearing-loss/26596728

The article appears to have been published online yesterday, and it is dated “Updated: 7:58 PM EST Mar 1, 2019″…

I have not had a chance to investigate, but I am wondering…

Was this clever plan to fast track FX-322 (if all goes well) by connecting it with dementia and other fast-track-friendly conditions mentioned anywhere else… before yesterday?

Was this real news or recycled news? Either way, it’s exciting to consider…

If all goes well, Frequency Therapeutics plans on asking the FDA to fast track the drug, citing recent studies that link hearing loss to other diseases like depression and dementia.

Can this “loophole” apply to other drugs, not just FX-322? and allow pharma companies to fast track promising tinnitus treatments as long as they are somehow related to “more serious” conditions and risks of withholding the drug (e.g. risk of suicide)? All these questions would certainly make for an eye-opening discussion.

Developing story…


Subscribe to Email Updates

Newsletter subscribers get early access to our latest articles. Expect 1 to 3 emails per week.

This field is for validation purposes and should be left unchanged.

No spam, no third parties, and 100% free. Your information is kept private. Unsubscribe with one click anytime.